At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
LUM-201drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Phase 2 Study to Evaluate Growth and Safety of LUM-201 Following 12 Months of Daily rhGH Treatment in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed the LUM-201-01 Trial
In Brief
A Phase 2 clinical trial evaluating LUM-201 for Growth Hormone Deficiency. Completed, enrolled 15 participants across 10 sites in 2 countries.
Detailed Summary
This is a multi-national trial. The goals of the trial are to study the growth response to LUM-201 administration in children with idiopathic growth hormone deficiency (GHD) previously treated with daily rhGH for 12 months in the LUM-201-01 trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGrowth Hormone Deficiency
CountriesPoland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartFeb 2022
First PostedFeb 2022
Primary CompletionJan 2025
TodayJul 2026
First PostedFeb 22, 2022
Enrollment StartFeb 18, 2022
Primary CompletionJan 22, 2025
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 4.4 years ago
Interventions
LUM-201drug
Administered orally once daily